Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Cross-bridge Cycle01:26

Cross-bridge Cycle

124.8K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
124.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Neural Regulation01:37

Neural Regulation

44.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.8K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.6K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial.

Muscle & nerve·2026
Same author

Optimizing Research Operations and Resource Utilization in ALS Care: Insights From the Tofersen Antisense Oligonucleotide Expanded Access Protocol.

Muscle & nerve·2026
Same author

Functional Activity of TDP-43: A Direct Biomarker for ALS.

medRxiv : the preprint server for health sciences·2026
Same author

Phosphorylated Tau at Threonine 181 Is Elevated in Amyotrophic Lateral Sclerosis Plasma.

Muscle & nerve·2026
Same author

Development of a machine learning-based survival prediction model for ALS inclusive of the advanced-stage population.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Nature·2026

Related Experiment Video

Updated: Mar 31, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.2K

Amyotrophic Lateral Sclerosis: Review.

Johnny S Salameh1, Robert H Brown1, James D Berry2

  • 1Department of Neurology, University of Massachusetts Medical School, University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts.

Seminars in Neurology
|October 28, 2015
PubMed
Summary
This summary is machine-generated.

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with a delayed diagnosis, often exceeding 12 months. Multidisciplinary care and emerging therapies offer hope for improved survival and quality of life for ALS patients.

More Related Videos

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.8K

Related Experiment Videos

Last Updated: Mar 31, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.2K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.8K

Area of Science:

  • Neurology
  • Neurodegenerative Diseases

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder impacting motor neurons.
  • Lifetime risk is higher in men and military veterans.
  • Diagnosis is clinical, supported by electrodiagnostics, with other conditions ruled out via imaging and labs.

Purpose of the Study:

  • To provide an overview of Amyotrophic Lateral Sclerosis (ALS).
  • To highlight diagnostic challenges and current management strategies.
  • To discuss ongoing research and therapeutic developments in ALS.

Main Methods:

  • Clinical diagnosis based on neurological examination.
  • Electrodiagnostic studies for confirmation.
  • Neuroimaging and laboratory tests to exclude alternative diagnoses.

Main Results:

  • Diagnosis of ALS is often delayed, averaging over 12 months from symptom onset.
  • Multidisciplinary care settings improve survival and quality of life for ALS patients.
  • Riluzole is the sole FDA-approved disease-modifying therapy, with numerous symptomatic treatments available.

Conclusions:

  • ALS diagnosis requires a comprehensive approach due to its complexity and exclusion criteria.
  • Multidisciplinary care is crucial for optimizing patient outcomes.
  • Intensive research into stem cell, gene, and small molecule therapies shows promise for future ALS treatments.